ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1605458
This article is part of the Research TopicEmerging Trends in Real-World Pharmacoepidemiology and Drug Safety: 2025View all articles
Influence of the estimated glomerular filtration rate equation on carboplatin dosing: a real-world study
Provisionally accepted
- 1Pharmacy Department, ULS Alto Ave, Guimarães, Portugal, Guimarães, Portugal
- 2Faculty of Pharmacy, University of Porto, Porto, Portugal
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Carboplatin is a renally excreted antineoplastic drug associated with myelotoxic effects. Doses are calculated according to the Calvert formula. The change from Cockcroft-Gault (CG) to the race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) may have an impact on doses. The aim of the study was to evaluate the difference in carboplatin doses based on estimated glomerular filtration rate (eGFR) calculated using the two different equations (i.e. CG and CKD-EPI) applied to a real-world dataset of carboplatin administrations.Materials and methods: Retrospective study simulating the effect of switching to CKD-EPI on doses calculated using CG. Real-world data were collected on all carboplatin doses administered in a general hospital oncology day-care unit during 2023. Doses originally calculated using CG estimates were recalculated using CKD-EPI results. A Bland-Altman analysis was performed to assess the discrepancies between the two equations. Correlations with anthropometric data were examined.Result: A total of 487 cycles were administered to 126 patients with a mean age of 58.3 years (SD 12.6), 60.3% were female. There was a significant mean difference (p<0.001) with a moderate effect (Cohen's d=0.474) between clearance calculated with CG and eGFR calculated with CKD-EPI. CKD-EPI calculated doses had a mean 52 mg higher (limits of agreement -107 +211). Percentage differences between CKD-EPI and CG doses ranged from +70.9% (CG=405mg, CKD-EPI=692mg) to -24.3% (CG=684mg, CKD-EPI=518mg). Differences were strongly correlated with body mass index (BMI) (p<0.001, R=0.681).Conclusion: Clinically relevant differences were found between carboplatin doses calculated with CG and CKD-EPI. These differences were more relevant in male patients with low BMI.
Keywords: Carboplatin, Drug-Related Side Effects and Adverse Reactions, Glomerular Filtration Rate, Renal Insufficiency, Retrospective Studies
Received: 03 Apr 2025; Accepted: 30 May 2025.
Copyright: © 2025 Fortunato, Barbosa, Araujo and Fernandez-Llimos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fernando Fernandez-Llimos, Faculty of Pharmacy, University of Porto, Porto, Portugal
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.